Institutional members access full text with Ovid®

Central neuregulin-1/ErbB signaling modulates cardiac function via sympathetic activity in pressure overload-induced heart failure

Matsukawa, Ryuichia; Hirooka, Yoshitakab; Ito, Kojia; Honda, Nobuhiroa; Sunagawa, Kenjia

doi: 10.1097/HJH.0000000000000072
ORIGINAL PAPERS: Neural mechanisms

Objectives: Neuregulin-1 (NRG-1)/ErbB signaling in the heart is reported to have a crucial role in heart failure. We recently demonstrated that NRG-1 signaling has sympathoinhibitory effects in the brain cardiovascular control center. How this central signaling impacts sympathoexcitation in heart failure, however, is unknown. Here we examined the role of central NRG-1/ErbB signaling in modulating the sympathetic nervous system in pressure overload-induced heart failure.

Methods and results: Pressure overload-induced heart failure was induced in Wistar–Kyoto rats by banding the abdominal aorta. Rats were followed up for 15 weeks. Compared to sham-operated rats, aortic-banded rats showed left ventricle (LV) hypertrophy, LV dilation, and LV dysfunction [reducing fractional shortening (%fractional shortening), increased LV end-diastolic pressure, decreased positive and negative pressure differential (±dp/dtmax)], and increased urinary norepinephrine excretion. Aortic banding led to reduced expression of NRG-1 in the brainstem at 10 weeks after banding and reduced expression of ErbB2 at 5 weeks, but did not affect ErbB4. Central administration of recombinant NRG-1β at 5 weeks for 2 weeks attenuated LV hypertrophy, improved LV dilatation, prevented LV dysfunction (improvement of %fractional shortening and ±dp/dtmax, and reduction of LV end-diastolic pressure), and lowered urinary norepinephrine excretion at 10 weeks, and these effects were still observed at 15 weeks.

Conclusion: NRG-1/ErbB signaling in the brainstem is impaired during the progression of pressure overload-induced heart failure. Activation of central NRG-1 signaling improves cardiac function through sympathoinhibition. These findings provide a new treatment concept and support the benefit of NRG-1 treatment in heart failure.

aDepartment of Cardiovascular Medicine

bDepartment of Advanced Cardiovascular Regulation and Therapeutics, Kyushu University Graduate School of Medical Sciences, Maidashi, Higashi-ku, Fukuoka, Japan

Correspondence to Yoshitaka Hirooka, MD, PhD, Department of Advanced Cardiovascular Regulation and Therapeutics, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Tel: +81 92 6425356; fax: +81 92 6425374; e-mail: hyoshi@cardiol.med.kyushu-u.ac.jp

Abbreviations: LVDd, left ventricle end-diastolic diameter; LVDs, left ventricle end-systolic diameter; LVEDP, left ventricle end-diastolic pressure; LVWT, left ventricle wall thickness; negative dP/dtmax, maximum rate of pressure reduction; NRG-1, neuregulin-1; positive dP/dtmax, maximum rate of pressure increase; rhNRG-1β, recombinant NRG-1β; RVLM, rostral ventrolateral medulla; SNS, sympathetic nervous system; uNE, urinary norepinephrine excretion; WKY rats, Wistar–Kyoto rats

Received 28 November, 2012

Accepted 8 November, 2013

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins